Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.50 |
| ▸ | PLG | P00747 | 1/20 | 0.50 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.50 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.50 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.50 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.50 |
| ▸ | CCKAR | P32238 | 3/20 | 0.48 |
| ▸ | CCKBR | P32239 | 2/20 | 0.48 |
| ▸ | GLP1R | P43220 | 12/20 | 0.47 |
| ▸ | GIPR | P48546 | 10/20 | 0.47 |
| ▸ | GCGR | P47871 | 6/20 | 0.47 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.46 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.45 |
| ▸ | AKT1 | P31749 | 1/20 | 0.43 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26346380 | 0.76 | GLP1R (0.60) | CCKBRGLP1RGIPRGCGRCXCR4 | |
| SCHEMBL12984108 | 0.75 | RAMP3 (0.62) | CXCR4 | |
| SCHEMBL12984633 | 0.75 | APLNR (0.49) | F2PLGPRSS1PRSS2PRSS3 | |
| SCHEMBL30409891 | 0.74 | EED (0.58) | GLP1RGIPRGCGRAKT1CXCR4 | |
| SCHEMBL10066201 | 0.73 | PRSS1 (0.49) | F2PLGPRSS1PRSS2PRSS3 | |
| SCHEMBL29904119 | 0.73 | MAGI3 (0.52) | CCKBRIL23RCXCR4 | |
| SCHEMBL30440014 | 0.73 | IL23R (0.59) | GLP1RGIPRIL23RPIN1CXCR4 | |
| SCHEMBL23710086 | 0.73 | PIN1 (0.51) | CCKARCCKBRPIN1CXCR4 | |
| SCHEMBL23700413 | 0.72 | PIN1 (0.53) | CCKARCCKBRPIN1CXCR4 | |
| SCHEMBL23700417 | 0.72 | PIN1 (0.53) | CCKARCCKBRPIN1CXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11766414-B2 | Compositions, delivery systems, and methods useful in tumor therapy | INDI MOLECULAR, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20220211648-A1 | COMPOSITIONS, DELIVERY SYSTEMS, AND METHODS USEFUL IN TUMOR THERAPY | INDI MOLECULAR, INC. | 2022-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11766414-B2 | Compositions, delivery systems, and methods useful in tumor therapy | TP53, BAX, RNASE1 | F2 462/4885PLG 65/4885PRSS1 1069/4885 |
| US-20220211648-A1 | COMPOSITIONS, DELIVERY SYSTEMS, AND METHODS USEFUL IN TUMOR THERAPY | TP53, BAX, RNASE1 | F2 462/4885PLG 65/4885PRSS1 1069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.